Collaboration between academics, small pharmaceutical company and patient organizations in the development of a new formulation of cysteamine in nephropathic cystinosis: A successful story - Archive ouverte HAL Access content directly
Journal Articles Thérapie Year : 2020

Collaboration between academics, small pharmaceutical company and patient organizations in the development of a new formulation of cysteamine in nephropathic cystinosis: A successful story

Georges Deschênes
  • Function : Author
  • PersonId : 889782
B. Kassai

Abstract

Rare diseases usually concern small and disseminated population. Implementing clinical research with the right design, outcomes measures and the recruitment of patients are challenges. Collaborations, training and multidisciplinary approach are often required. In this article, we provide an overview of a successful collaboration in nephropathic cystinosis (NC), focusing on what was the key of success, the interactions between academics, the pharmaceutical company and patients organizations. NC is considered as a very rare disease. In 2010, a new formulation of cysteamine, the only available treatment to improve renal outcome of the disease, was proposed by a small American company. Studies were implemented in France under the coordination of an expert of the disease and the clinical investigation center of Lyon. The collaboration resulted in a good recruitment and retention of the patients in the study and most of all in the availability of the new formulation in France. Patients could have facilitated the research by being involved in the early stages of the studies. Involving patients and public early in the process is particularly important in rare diseases as the patient is a great source of knowledge and has his own expectations. Priorities of research, design, conduct and reporting of clinical trials can be defined in collaboration with adults but also with young patients or public, the first concerned in rare diseases. This concept is still to be developed and improved especially with paediatric patients.
Fichier principal
Vignette du fichier
S0040595720300135.pdf (165.31 Ko) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

hal-02901890 , version 1 (20-05-2022)

Licence

Attribution - NonCommercial

Identifiers

Cite

Ségolène Gaillard, Laurent Roche, Georges Deschênes, Denis E. J. Morin, Christine Vianey-Saban, et al.. Collaboration between academics, small pharmaceutical company and patient organizations in the development of a new formulation of cysteamine in nephropathic cystinosis: A successful story. Thérapie, 2020, 75 (2), pp.169--173. ⟨10.1016/j.therap.2020.02.008⟩. ⟨hal-02901890⟩
90 View
73 Download

Altmetric

Share

Gmail Facebook X LinkedIn More